The ability of the RIG-I agonist M8 to push cells toward a pro-inflammatory phenotype through the production of type I IFNs and lymphocyte-recruiting chemokines makes this compound a suitable candidate to enhance cell death in HPV+ cancer cells and improve the effectiveness of existing anticancer therapies against HPV-associated cancer. The gene discussed is RIGI; the disease is cancer.